What is William Blair’s Estimate for Biodesix Q1 Earnings?

Biodesix, Inc. (NASDAQ:BDSX) – William Blair issued their Q1 2026 EPS estimates for shares of Biodesix in a research note issued to investors on Tuesday, March 4th. William Blair analyst A. Brackmann forecasts that the company will earn ($0.05) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Biodesix’s current full-year earnings is ($0.35) per share. William Blair also issued estimates for Biodesix’s Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.14) EPS.

Biodesix Stock Performance

Shares of BDSX stock opened at $0.72 on Wednesday. The firm has a market cap of $104.74 million, a P/E ratio of -1.85 and a beta of 1.06. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40. Biodesix has a fifty-two week low of $0.64 and a fifty-two week high of $2.04. The stock’s 50-day moving average is $1.11 and its two-hundred day moving average is $1.41.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The business had revenue of $20.43 million during the quarter, compared to analyst estimates of $19.92 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. AIGH Capital Management LLC boosted its position in Biodesix by 8.8% during the fourth quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company’s stock worth $9,455,000 after purchasing an additional 500,000 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Biodesix during the 3rd quarter worth $10,849,000. Birchview Capital LP raised its holdings in Biodesix by 0.7% in the 4th quarter. Birchview Capital LP now owns 5,581,176 shares of the company’s stock worth $8,539,000 after acquiring an additional 40,000 shares during the period. Silverarc Capital Management LLC lifted its position in Biodesix by 21.7% during the 4th quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company’s stock worth $6,628,000 after acquiring an additional 771,187 shares during the last quarter. Finally, Samjo Management LLC bought a new stake in Biodesix during the fourth quarter valued at about $3,790,000. 20.96% of the stock is owned by institutional investors.

Insider Activity at Biodesix

In other Biodesix news, CEO Scott Hutton sold 83,660 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $76,967.20. Following the completion of the sale, the chief executive officer now owns 701,947 shares of the company’s stock, valued at $645,791.24. The trade was a 10.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders have sold 128,702 shares of company stock valued at $118,406. 69.20% of the stock is currently owned by corporate insiders.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.